Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D A Goodkin

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
American Journal of Nephrology|July 8, 1998
Effects of Epoetin alfa on hemostasis in chronic renal failureW W Tang, R A Stead, D A Goodkin
Seminars in Dialysis|June 26, 2001
The dialysis outcomes and practice patterns study (DOPPS): how can we improve the care of hemodialysis patients?D A Goodkin, D L Mapes, P J Held
Clinics in Endocrinology and Metabolism|July 1, 1984
The role of the anion gap in detecting and managing mixed metabolic acid-base disordersD A Goodkin, G G Krishna, R G Narins
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 26, 1999
The Normal Haematocrit Trial in dialysis patients with cardiac diseaseA Besarab, W K Bolton, A R Nissenson, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 5, 1997
Target haematocrit during erythropoietin therapyA R Nissenson, A Besarab, W K Bolton, et al.
Kidney International|July 8, 2000
A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidismW G Goodman, J M Frazao, D A Goodkin, et al.
Clinical Nephrology|July 15, 1999
Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: a post hoc analysisD A Goodkin, L F Gimenez, S E Graber, et al.
The New England Journal of Medicine|August 27, 1998
The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetinA Besarab, W K Bolton, J K Browne, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 1, 1995
Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patientsE P Paganini, J W Eschbach, J M Lazarus, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
American Journal of Nephrology|July 8, 1998
Effects of Epoetin alfa on hemostasis in chronic renal failureW W Tang, R A Stead, D A Goodkin
Seminars in Dialysis|June 26, 2001
The dialysis outcomes and practice patterns study (DOPPS): how can we improve the care of hemodialysis patients?D A Goodkin, D L Mapes, P J Held
Clinics in Endocrinology and Metabolism|July 1, 1984
The role of the anion gap in detecting and managing mixed metabolic acid-base disordersD A Goodkin, G G Krishna, R G Narins
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 26, 1999
The Normal Haematocrit Trial in dialysis patients with cardiac diseaseA Besarab, W K Bolton, A R Nissenson, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 5, 1997
Target haematocrit during erythropoietin therapyA R Nissenson, A Besarab, W K Bolton, et al.
Kidney International|July 8, 2000
A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidismW G Goodman, J M Frazao, D A Goodkin, et al.
Clinical Nephrology|July 15, 1999
Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: a post hoc analysisD A Goodkin, L F Gimenez, S E Graber, et al.
The New England Journal of Medicine|August 27, 1998
The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetinA Besarab, W K Bolton, J K Browne, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 1, 1995
Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patientsE P Paganini, J W Eschbach, J M Lazarus, et al.
Pageof 2